ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Nogapendekin alfa inbakicept is on this study

  • The record lists it as a treatment, written “N-803”.
  • A model not recorded judged it tested: part of what the study tests. Nov 1, 2026, 4:45 AM UTC
  • The role rule says the same.
  • So Nogapendekin alfa inbakicept's page lists this study under “Testing it”.
4 links0 made here, not in the record7 judgments2 judges (the rules as one: Rule based)0 record changes seen
Model not recordedRule based
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT04847466Immunotherapy Combination:Irradiated PD-L1 CAR-NKCells Plus PembrolizumabPlus N-803 for SubjectsWith Recurrent/MetastaticGastric or Head and NeckCancerNational Cancer Institute (NCIPhase 2 · completedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSNeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSNogapendekin alfa inbakiceptEntry “N-803”, read by our name rule›Nov 1 · A model not recorded · TestedNov 18 · Rule based · TestedTestedPembrolizumabIntervention entry›Nov 1 · A model not recorded · BackgroundNov 18 · Rule based · BackgroundBackgroundAllogeneic PD-L1 Tumor-targ…Entry “PD-L1 t-haNK”, read by our nam…›Nov 1 · A model not recorded · TestedNov 18 · Rule based · BackgroundTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
Nov 1Nogapendekin alfa inbakiceptA model not recordedTestedCurrent
Nov 1PembrolizumabA model not recordedBackgroundCurrent
Nov 1Allogeneic PD-L1 Tumor-targeted High-affinity Natural Killer CellsA model not recordedTestedCurrent
Nov 18Nogapendekin alfa inbakiceptRule based · role ruleTestedAgrees
Nov 18PembrolizumabRule based · role ruleBackgroundAgrees
Nov 18Allogeneic PD-L1 Tumor-targeted High-affinity Natural Killer CellsRule based · role ruleBackgroundOverridden
As of nowNeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.